G1 Therapeutics Inc (GTHX) Short Interest Update

G1 Therapeutics Inc (NASDAQ:GTHX) was the target of a significant growth in short interest in December. As of December 29th, there was short interest totalling 697,343 shares, a growth of 29.0% from the December 15th total of 540,660 shares. Based on an average daily volume of 124,734 shares, the short-interest ratio is presently 5.6 days. Currently, 4.3% of the shares of the stock are short sold.

GTHX has been the subject of several analyst reports. Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. BidaskClub upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, BTIG Research initiated coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They issued a “buy” rating and a $38.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. G1 Therapeutics has an average rating of “Buy” and a consensus target price of $31.40.

In related news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $20.01, for a total value of $4,002,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark A. Velleca sold 7,500 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $20.01, for a total value of $150,075.00. The disclosure for this sale can be found here. Insiders sold 542,156 shares of company stock valued at $10,761,689 over the last 90 days.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new position in shares of G1 Therapeutics during the third quarter worth $319,000. Schwab Charles Investment Management Inc. purchased a new position in shares of G1 Therapeutics during the third quarter worth $364,000. American International Group Inc. purchased a new position in shares of G1 Therapeutics during the third quarter worth $130,000. Chartwell Investment Partners LLC boosted its position in shares of G1 Therapeutics by 5.0% during the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock worth $2,303,000 after buying an additional 4,388 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of G1 Therapeutics during the third quarter worth $568,000. Institutional investors and hedge funds own 43.25% of the company’s stock.

G1 Therapeutics (NASDAQ GTHX) opened at $23.04 on Friday. G1 Therapeutics has a 52-week low of $12.04 and a 52-week high of $28.67. The company has a market capitalization of $653.08 and a price-to-earnings ratio of -10.72.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.themarketsdaily.com/2018/01/14/g1-therapeutics-inc-gthx-short-interest-update.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply